148 results
8-K
EX-99.1
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
analyses. SLS-005 was generally well-tolerated and comparable to placebo in safety. There was an imbalance of deaths/death equivalents observed
8-K
EX-99.2
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
studies measuring time to tracheostomy or death. Neither study showed a statistically significant difference in mortality at the end of the study . https
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
of protein aggregates within cells, whether in the CNS or in muscle, and eventually leads to loss of function and ultimately cell death. Prior preclinical … of directors resulting from death, resignation, retirement, disqualification, removal from office or other cause shall, unless otherwise provided
424B5
83vczy92i3lolbo
30 Jan 24
Prospectus supplement for primary offering
6:05am
424B5
oi8plmf8e64
30 Nov 23
Prospectus supplement for primary offering
4:58pm
424B5
qsbdmundfj1v0nbjxd9i
28 Nov 23
Prospectus supplement for primary offering
4:06pm
424B3
t9laepll 07ta6
29 Sep 23
Prospectus supplement
4:56pm
424B5
kzyw8nnx 3zv
25 Sep 23
Prospectus supplement for primary offering
6:02am
8-K
EX-99.2
6ga7 rn6x5
20 Sep 23
Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide
7:00am